BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Zealand Pharma readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Zealand Pharma's drugs run\, from
  ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07589686-162@assetmemo.bio
DTSTAMP:20261121T005856Z
DTSTART;VALUE=DATE:20271112
DTEND;VALUE=DATE:20271113
SUMMARY:petrelintide: Phase 2 readout est. (NCT07589686)
DESCRIPTION:petrelintide\, phase 2\, Obesity.\nStudy: A Dose-Finding Study 
 of Petrelintide With Enicepatide (RO7795068) in Adults With Obesity or Ove
 rweight\nEstimated primary completion: 12 November 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/petrelintide#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07589686
URL:https://assetmemo.bio/drug/petrelintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07754461-119@assetmemo.bio
DTSTAMP:20261121T005856Z
DTSTART;VALUE=DATE:20280117
DTEND;VALUE=DATE:20280118
SUMMARY:survodutide: Phase 3 readout est. (NCT07754461)
DESCRIPTION:survodutide\, phase 3\, Type 2 Diabetes.\nStudy: A Study to Tes
 t Whether Survodutide Helps People With Type 2 Diabetes Control Their Bloo
 d Sugar\nEstimated primary completion: 17 January 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/survodutide#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07754461
URL:https://assetmemo.bio/drug/survodutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07850050-119@assetmemo.bio
DTSTAMP:20261121T005856Z
DTSTART;VALUE=DATE:20280726
DTEND;VALUE=DATE:20280727
SUMMARY:survodutide: Phase 3 readout est. (NCT07850050)
DESCRIPTION:survodutide\, phase 3\, Obesity.\nStudy: SYNCHRONIZE®-HERA: A 
 Study to Test Whether Survodutide Helps Women Who Are Living With Overweig
 ht or Obesity and Are Going Through or Have Finished Menopause\, to Lose W
 eight\nEstimated primary completion: 26 July 2028. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/survodutide#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07850050
URL:https://assetmemo.bio/drug/survodutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07843485-162@assetmemo.bio
DTSTAMP:20261121T005856Z
DTSTART;VALUE=DATE:20281020
DTEND;VALUE=DATE:20281021
SUMMARY:petrelintide: Phase 3 readout est. (NCT07843485)
DESCRIPTION:petrelintide\, phase 3\, Obesity.\nStudy: A Phase III Study to 
 Evaluate the Efficacy and Safety of Petrelintide in Participants With Over
 weight or Obesity and Type 2 Diabetes\nEstimated primary completion: 20 Oc
 tober 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/petrelint
 ide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07843485
URL:https://assetmemo.bio/drug/petrelintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07843498-162@assetmemo.bio
DTSTAMP:20261121T005856Z
DTSTART;VALUE=DATE:20281221
DTEND;VALUE=DATE:20281222
SUMMARY:petrelintide: Phase 3 readout est. (NCT07843498)
DESCRIPTION:petrelintide\, phase 3\, Obesity.\nStudy: A Phase III Study to 
 Evaluate the Efficacy and Safety of Petrelintide in Participants With Over
 weight or Obesity\nEstimated primary completion: 21 December 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/petrelintide#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07843498
URL:https://assetmemo.bio/drug/petrelintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07850063-119@assetmemo.bio
DTSTAMP:20261121T005856Z
DTSTART;VALUE=DATE:20290429
DTEND;VALUE=DATE:20290430
SUMMARY:survodutide: Phase 3 readout est. (NCT07850063)
DESCRIPTION:survodutide\, phase 3\, Obesity.\nStudy: ELEVATE-LIVER: A Study
  to Test Whether Survodutide Helps Improve Heart Structure and Function in
  People With Overweight or Obesity and Fatty Liver Disease\nEstimated prim
 ary completion: 29 April 2029. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/survodutide#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07850063
URL:https://assetmemo.bio/drug/survodutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06632457-119@assetmemo.bio
DTSTAMP:20261121T005856Z
DTSTART;VALUE=DATE:20290605
DTEND;VALUE=DATE:20290606
SUMMARY:survodutide: Phase 3 readout est. (NCT06632457)
DESCRIPTION:survodutide\, phase 3\, MASH / NASH.\nStudy: LIVERAGE™ - Cirr
 hosis: A Study to Test Whether Survodutide Helps People With a Liver Disea
 se Called NASH/MASH Who Have Cirrhosis\nEstimated primary completion: 5 Ju
 ne 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/survodutide#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0663
 2457
URL:https://assetmemo.bio/drug/survodutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07855900-119@assetmemo.bio
DTSTAMP:20261121T005856Z
DTSTART;VALUE=DATE:20291106
DTEND;VALUE=DATE:20291107
SUMMARY:survodutide: Phase 3 readout est. (NCT07855900)
DESCRIPTION:survodutide\, phase 3\, Obesity.\nStudy: SYNCHRONIZE®-START- A
  Study to Test Whether Survodutide Helps People Living With Overweight or 
 Obesity Who do Not Have Diabetes to Lose Weight\nEstimated primary complet
 ion: 6 November 2029. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /survodutide#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07855900
URL:https://assetmemo.bio/drug/survodutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07843472-162@assetmemo.bio
DTSTAMP:20261121T005856Z
DTSTART;VALUE=DATE:20300728
DTEND;VALUE=DATE:20300729
SUMMARY:petrelintide: Phase 3 readout est. (NCT07843472)
DESCRIPTION:petrelintide\, phase 3\, Obesity.\nStudy: A Phase III Study to 
 Evaluate the Efficacy and Safety of Petrelintide in Participants With Over
 weight or Obesity and Established Cardiovascular Disease\nEstimated primar
 y completion: 28 July 2030. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/petrelintide#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07843472
URL:https://assetmemo.bio/drug/petrelintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06632444-119@assetmemo.bio
DTSTAMP:20261121T005856Z
DTSTART;VALUE=DATE:20311227
DTEND;VALUE=DATE:20311228
SUMMARY:survodutide: Phase 3 readout est. (NCT06632444)
DESCRIPTION:survodutide\, phase 3\, MASH / NASH.\nStudy: LIVERAGE™: A Stu
 dy to Test Whether Survodutide Helps People With a Liver Disease Called NA
 SH/MASH Who Have Moderate or Advanced Liver Fibrosis\nEstimated primary co
 mpletion: 27 December 2031. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/survodutide#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06632444
URL:https://assetmemo.bio/drug/survodutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
